Form 4: Dermata Therapeutics Director Acquires 5,000 Stock Options
SEC Form 4
Dermata Therapeutics director Wendell Wierenga acquired 5,000 stock options at an exercise price of $1.38 on January 13, 2025.
Summary
- Wendell Wierenga, a director at Dermata Therapeutics, acquired 5,000 stock options on January 13, 2025.
- The exercise price for these options is $1.38 per share.
- The options vest in twelve equal monthly installments starting one month after the grant date, subject to continuous service.
- The options expire on January 12, 2035.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of a stock option grant to a director. It is neither particularly positive nor negative, but it does indicate that a director has a vested interest in the company's performance.
Positives
- The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.
Risks
- The vesting of the options is contingent on the director's continuous service, which introduces a risk of forfeiture if service is terminated.
Future Outlook
The document does not contain any forward-looking statements or guidance.
Industry Context
This is a standard Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure required by the SEC.
Comparison to Industry Standards
- Stock option grants to directors are a common practice in publicly traded companies as a form of compensation and incentive.
- The vesting schedule of monthly installments over a year is a typical vesting structure.
- The exercise price of $1.38 is specific to Dermata Therapeutics and would need to be compared to other companies in the same sector to assess its relative value.
Stakeholder Impact
- The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's success.
Key Dates
| Date | Description |
|---|---|
| 01/13/2025 | Date of stock option acquisition. |
| 01/14/2025 | Date of filing the Form 4. |
| 01/12/2035 | Expiration date of the stock options. |
Keywords
stock options, insider trading, Dermata Therapeutics, director, Wendell Wierenga, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.